Strategic funding CereGate has secured early-stage and growth funding from notable investors (High-Tech Gründerfonds and Heal Capital), signaling investor confidence and potential for partnerships or joint ventures to accelerate product development and go-to-market initiatives.

Neurotech focus Specialized in non-invasive to minimally invasive computer-brain interface solutions with neuromodulation platform capabilities, presenting opportunities to collaborate with medical device manufacturers, healthcare providers, and research institutions seeking advanced sensory restoration and gait impairment therapies.

Trials and partnerships With successful human trials and strong industry partnerships, there is a pathway for early-adopter customers, pilot programs, and co-development deals to validate system integration with existing implants and neuromodulation therapies.

Software platform A software-centric approach to programming neuromodulation systems geared toward personalized therapy opens sales potential for clinics and hospitals requiring adaptable programming tools and remotely managed therapy workflows.

Market positioning Operating in a niche yet high-growth segment of neurotechnology with a small team, CereGate presents an opportunity for strategic partnerships to scale commercialization, leverage investor visibility, and differentiate from larger competitors through focused, value-driven solutions.